tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inozyme downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Inozyme (INZY) to Neutral from Outperform with a price target of $4, down from $7, after BioMarin entered into an agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of $270M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1